Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cumberland Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Cumberland Pharmaceuticals shares (CPIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cumberland Pharmaceuticals employs 94 staff and has a trailing 12-month revenue of around USD$49.6 million.
|Latest market close||USD$2.99|
|52-week range||USD$2.77 - USD$5.44|
|50-day moving average||USD$2.9968|
|200-day moving average||USD$3.1816|
|Wall St. target price||USD$8.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.291|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-3.24%|
|1 month (2020-12-15)||-0.33%|
|3 months (2020-10-15)||-1.97%|
|6 months (2020-07-15)||-9.12%|
|1 year (2020-01-15)||-41.60%|
|2 years (2019-01-15)||-48.57%|
|3 years (2018-01-12)||7.08|
|5 years (2016-01-15)||4.93|
Valuing Cumberland Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cumberland Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cumberland Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.8 million.
The EBITDA is a measure of a Cumberland Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$49.6 million|
|Gross profit TTM||USD$38.8 million|
|Return on assets TTM||-1.17%|
|Return on equity TTM||-5.11%|
|Market capitalisation||USD$46 million|
TTM: trailing 12 months
There are currently 97,925 Cumberland Pharmaceuticals shares held short by investors – that's known as Cumberland Pharmaceuticals's "short interest". This figure is 1% up from 96,924 last month.
There are a few different ways that this level of interest in shorting Cumberland Pharmaceuticals shares can be evaluated.
Cumberland Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Cumberland Pharmaceuticals shares currently shorted divided by the average quantity of Cumberland Pharmaceuticals shares traded daily (recently around 33767.24137931). Cumberland Pharmaceuticals's SIR currently stands at 2.9. In other words for every 100,000 Cumberland Pharmaceuticals shares traded daily on the market, roughly 2900 shares are currently held short.
However Cumberland Pharmaceuticals's short interest can also be evaluated against the total number of Cumberland Pharmaceuticals shares, or, against the total number of tradable Cumberland Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cumberland Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cumberland Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0107% of the tradable shares (for every 100,000 tradable Cumberland Pharmaceuticals shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cumberland Pharmaceuticals.
Find out more about how you can short Cumberland Pharmaceuticals stock.
We're not expecting Cumberland Pharmaceuticals to pay a dividend over the next 12 months.
Cumberland Pharmaceuticals's shares were split on a 2:1 basis on 6 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cumberland Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cumberland Pharmaceuticals shares which in turn could have impacted Cumberland Pharmaceuticals's share price.
Over the last 12 months, Cumberland Pharmaceuticals's shares have ranged in value from as little as $2.77 up to $5.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cumberland Pharmaceuticals's is 0.3297. This would suggest that Cumberland Pharmaceuticals's shares are less volatile than average (for this exchange).
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care and gastroenterology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.